Skip to content
Screener

C4 Therapeutics CCCC Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$6.2MBeat by $1.8M
EPS-$0.20Beat by $0.05
Revenue estimate$4.4M
EPS estimate-$0.25

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$4.8M
EPS estimate-$0.21

FAQ

When did C4 Therapeutics report Q1 2026 earnings?
C4 Therapeutics (CCCC) reported Q1 2026 earnings on May 12, 2026 before market open.
What were C4 Therapeutics's Q1 2026 revenue and EPS?
C4 Therapeutics reported revenue of $6.2M and eps of $-0.20 for Q1 2026.
Did C4 Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.4M by $1.8M. EPS beat the consensus estimate of $-0.25 by $0.05.
How did C4 Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 14.3% from $7.2M a year earlier and eps grew 45.9% from $-0.37.
Where can I find C4 Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-033861) and the 10-Q periodic report (0001628280-26-033865) directly on SEC EDGAR. The filing index links above go to sec.gov.